ROBIN HINER: Open Payments
NPI 1851099329 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,661 in 95 payments from 12 companies in 2025. Trend: 2023 $140 · 2024 $519 · 2025 $1,661
Food & beverage: $1,661
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 12 | $308 |
| Neurocrine BioSciences, Inc. | 14 | $301 |
| Otsuka America Pharmaceutical, Inc. | 14 | $271 |
| E.R. Squibb & Sons, L.L.C. | 19 | $213 |
| Teva Pharmaceuticals USA, Inc. | 15 | $194 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $181 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| Janssen Pharmaceuticals, Inc | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
Products named: INGREZZA, ARISTADA, REXULTI, COBENFY, CAPLYTA, UZEDY, Auvelity, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
